静脉-静脉体外膜氧合低强度与中等强度抗凝:静脉-静脉体外膜氧合抗凝策略先导试验
该多中心平行组随机先导试验在美国3个中心纳入26例接受静脉-静脉体外膜氧合(ECMO)的危重成人,随机接受低强度或中等强度抗凝,以评估开展大型多中心随机试验的可行性。全部26例均接受了所分配强度的抗凝。主要疗效终点大出血在低强度组12例中发生1例(8.3%),中等强度组14例中发生4例(28.6%),绝对风险差-20.2个百分点(95%CI -48.6至8.1,P=.33)。主要安全终点血栓栓塞事件低强度组1例(8.3%),中等强度组0例,差异8.3个百分点(95%CI -7.3至24.0,P=.46)。低强度组出院前无死亡,中等强度组出院前死亡2例(14.3%),两例均发生大出血。作者认为入组和组间分离可行,需要并似乎可行开展大型多中心随机试验。
要点
- 静脉-静脉ECMO危重成人低强度vs中等强度抗凝先导试验中,26例全部接受所分配抗凝强度,入组与组间分离可行。
- 大出血低强度组1/12(8.3%)vs中等强度组4/14(28.6%),绝对风险差-20.2个百分点(95%CI -48.6至8.1,P=.33),未达统计学显著。
- 血栓栓塞事件低强度组1例(8.3%)vs中等强度组0例,差异8.3个百分点(95%CI -7.3至24.0,P=.46),未达统计学显著。
- 出院前死亡低强度组0例vs中等强度组2例(14.3%),两例死亡者均发生大出血。
- 作者认为该先导试验结果支持开展大型多中心随机试验,且似乎可行。
适用人群与场景
- 美国3个中心收治的接受静脉-静脉体外膜氧合(ECMO)的危重成人。
研究设计与关键结果
- 研究类型:多中心、平行组、随机先导试验,在美国3个中心开展,共纳入26例接受静脉-静脉ECMO的危重成人。
- 干预与对照:随机分配至低强度抗凝组(12例)或中等强度抗凝组(14例),全部26例均接受了所分配强度的抗凝。
- 可行性:以入组率和对抗凝策略的依从性评估,结果表明入组和组间分离可行。
- 主要疗效终点大出血(入组至拔管后24小时):低强度组1/12(8.3%)vs中等强度组4/14(28.6%),绝对风险差-20.2个百分点(95%CI -48.6至8.1,P=.33)。
- 主要安全终点血栓栓塞事件:低强度组1例(8.3%)vs中等强度组0例,差异8.3个百分点(95%CI -7.3至24.0,P=.46)。
- 出院前死亡:低强度组0例vs中等强度组2例(14.3%),两例均发生大出血。
证据类型、等级与局限
- 证据类型:多中心、平行组、随机先导试验(ClinicalTrials.gov注册号NCT04997265)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,静脉-静脉ECMO危重成人低强度vs中等强度抗凝的多中心随机试验中入组和组间分离可行,需要并似乎可行开展大型多中心随机试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bleeding is a common and sometimes fatal complication of venovenous extracorporeal membrane oxygenation (ECMO). Whether lowering the intensity of anticoagulation during venovenous ECMO is safe or effective is unknown.
RESEARCH QUESTION: Is a large, multicenter randomized trial of low-intensity vs moderate-intensity anticoagulation during venovenous ECMO feasible?
STUDY DESIGN AND METHODS: In a multicenter, parallel-group, randomized pilot trial conducted at 3 centers across the United States, we randomly assigned critically ill adults undergoing venovenous ECMO to low-intensity or moderate-intensity anticoagulation. Feasibility was assessed by enrollment rate and adherence to the assigned anticoagulation strategy. The primary efficacy outcome was major bleeding, and the primary safety outcome was thromboembolic events, both assessed between enrollment and 24 hours after decannulation.
RESULTS: All of the 26 patients enrolled received the assigned intensity of anticoagulation. A major bleeding event occurred in 1 of 12 patients (8.3%) in the low-intensity anticoagulation group and in 4 of 14 patients (28.6%) in the moderate-intensity anticoagulation group (absolute risk difference, -20.2 percentage points; 95% CI, -48.6 to 8.1; P = .33). One patient experienced a thromboembolic event (8.3%) in the low-intensity anticoagulation group compared with none in the moderate-intensity group (difference, 8.3 percentage points; 95% CI, -7.3 to 24.0; P = .46). No patients died before discharge in the low-intensity anticoagulation group, compared with 2 patients (14.3%) in the moderate-intensity group, both of whom experienced major bleeding events. No patients died before discharge in the low-intensity anticoagulation group, compared with 2 patients (14.3%) in the moderate-intensity group, both of whom experienced major bleeding events.
INTERPRETATION: Our results indicate that enrollment and separation between groups are feasible in a multicenter randomized trial of low-intensity vs moderate-intensity anticoagulation for critically ill adults receiving venovenous ECMO. A large, multicenter, randomized trial is needed and seems to be feasible.
CLINICAL TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04997265; URL: www.
CLINICALTRIALS: gov.
参考来源
- Gannon WD, Pratt EH, Vogelsong MA, et al. Low-Intensity vs Moderate-Intensity Anticoagulation for Venovenous Extracorporeal Membrane Oxygenation: The Strategies for Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation Pilot Trial. Chest. 2025. PMID: 40081660. doi:10.1016/j.chest.2025.02.032
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。